DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mustargen (Mechlorethamine Hydrochloride (Nitrogen Mustard)) - Current Clinical Trials

 
 



Mustargen Related Clinical Trials

Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2) [Completed]

Observational US Study Assessing Outcomes, Treatment Patterns, AEs, QOL in MF-CTCL Patients and Treated With Valchlor [Recruiting]

Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides [Completed]

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides [Completed]

Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients [Completed]

Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients [Completed]

Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors [Completed]

Helium:Oxygen Noninvasive Positive Pressure Ventilation in Patients Exposed to Sulfur Mustard [Completed]

Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis [Recruiting]

Psychophysiological Effects of Thorax Wraps With Ginger and Mustard Flour [Enrolling by invitation]

Examination of the Effects of Four Different Spices on Energy Metabolism [Completed]

Experimental Denture Pastes [Completed]

A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer [Completed]

Impact of Sunflower Seed Oil Massage on Neonatal Mortality and Morbidity in Nepal [Recruiting]

Glycemic and Satiety Response Study of Fibre-Enriched Pudding Products [Recruiting]

Use of Erythromycin in Mustard-Induced Bronchiolitis [Completed]

Use of Clarithromycin in Mustard-Induced Bronchiolitis [Completed]

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies [Active, not recruiting]

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis [Not yet recruiting]

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma [Not yet recruiting]

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Not yet recruiting]

JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis [Recruiting]

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma [Recruiting]

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma [Recruiting]

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma [Active, not recruiting]

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors [Recruiting]

Lenalidomide in Treating Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma [Active, not recruiting]

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma [Recruiting]

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma [Active, not recruiting]

Noninvasive Positive Pressure Ventilation Using Helium:Oxygen Versus Air:Oxygen in Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients Exposed to Sulfur Mustard [Completed]

Study of ZIO-201 in Advanced Sarcoma [Completed]

Effects of a Specific Spice on Energy Metabolism [Completed]

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma [Recruiting]

Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG [Active, not recruiting]

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma [Active, not recruiting]

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma [Active, not recruiting]

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma [Active, not recruiting]

Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection [Active, not recruiting]

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma [Active, not recruiting]

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease [Completed]

Radiation Therapy or No Radiation Therapy Following Chemotherapy in Treating Patients With Stage III or Stage IV Hodgkin's Disease [Active, not recruiting]

Eplerenone in Systemic Right Ventricle [Completed]

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation [Recruiting]

Combined Cord Blood and Haploidentical Transplantation for Patients With Hematologic Malignancies [Recruiting]

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas [Recruiting]

Therapy for Children With Advanced Stage Neuroblastoma [Recruiting]

KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy [Recruiting]

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas [Recruiting]

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma [Completed]

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors [Active, not recruiting]

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors [Terminated]

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia [Completed]

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia [Completed]

Melphalan With BBBD in Treating Patients With Brain Malignancies [Suspended]

Auriculotherapy as a Coping Strategy in Professional Nursing [Completed]

Application of Auriculotherapy on Nursing Professional Stress Levels [Completed]

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors [Completed]

Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse [Recruiting]

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma [Recruiting]

Allogeneic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma [Not yet recruiting]

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients [Recruiting]

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation [Recruiting]

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma [Recruiting]

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older [Recruiting]

Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors [Recruiting]

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease [Completed]

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma [Completed]

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma [Completed]

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma [Withdrawn]

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies [Recruiting]

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission [Recruiting]

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia [Recruiting]

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma [Suspended]

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma [Withdrawn]

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma [Withdrawn]

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Active, not recruiting]

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma [Recruiting]

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma [Withdrawn]

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin [Recruiting]

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma [Recruiting]

Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy [Recruiting]

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma [Withdrawn]

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders [Active, not recruiting]

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy [Recruiting]

Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma [Active, not recruiting]

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor [Active, not recruiting]

Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Active, not recruiting]

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors [Active, not recruiting]

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma [Withdrawn]

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma [Completed]

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma [Active, not recruiting]

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma [Active, not recruiting]

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma [Active, not recruiting]

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017